API | clofibrate

clofibrate (atromid-s) Report issue

Small molecule Approved ^FDA Priority Review ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW

Clofibrate is a lipid-lowering agent used for controlling the high cholesterol and triacylglyceride level in the blood. It belongs to the class of fibrates. It increases lipoprotein lipase activity to promote the conversion of VLDL to LDL, and hence reduce the level of VLDL. It can increase the level of HDL as well. ^Wikipedia

Chemistry

SMILES: COc1ccccc1N1CCN(CCCNc2cc(=O)n(C)c(=O)n2C)CC1
InChIKey: ICMGLRUYEQNHPF-UHFFFAOYSA-N
Mol. Mass: 387.48
ALogP: 0.72 Partition coefficient
ChEMBL Molecules:

urapidil

urapidil hydrochloride

clofibrate

More Chemistry

Pharmacology

Mechanism of Action:
- Peroxisome proliferator-activated receptor alpha (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Discontinued
Delivery Methods: Missing data
Pro Drug: No

Organizations (9)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (7)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (1)

Hypercholesterolemia (approved 1967)

Experimental Indications - Clinical Trial Phases 1-4 (5)

Cardiovascular Diseases (Phase 3)

Coronary Disease (Phase 3)

Heart Diseases (Phase 3)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 2
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue